Abstract
The cell cycle is a highly conserved and ordered set of events, culminating in cell growth and division. It is tightly controlled by many regulatory mechanisms that either permit or restrain its progression. The main families of regulatory proteins that play key roles in controlling cell cycle progression are the cyclins, the cyclin dependent kinases (Cdks), their substrate proteins, the Cdk inhibitors (CKI) and the tumor suppressor gene products, p53 and pRb. Many cell cycle control genes, when deregulated, can cause cells that are not dividing to enter the cell cycle and begin to proliferate leading to cancer development. They do so by interfacing with the basic cell cycle-regulatory machinery to activate cell cycle entry. There is at present much optimism about the possibility of finding anticancer drug treatment strategies that modulate cell cycle regulatory molecules. Candidate targets for such strategies include crucial cell cycle molecules involved in G1 to S phase or G2 to M phase transition. This review will outline the basic regulatory machinery responsible for catalyzing cell cycle entry and describe the latest advances made in the field of cell cycle regulation. The basis of targeting the cell cycle particularly the Cdks as an approach to developing novel, specific and perhaps more effective anticancer treatments will be discussed. Examples of novel cell cycle-targeting agents that are in, or are close to being in clinical trials will be provided.
Keywords: anticancer drugs, cancer therapy, cell cycle, cell cycle arrest, cyclins, cyclin dependent kinase(cdk), cdk inhibitors
Current Cancer Drug Targets
Title: Modulating Cell Cycle: Current Applications and Prospects for Future Drug Development
Volume: 2 Issue: 4
Author(s): Hala Gali-Muhtasib and Nadine Bakkar
Affiliation:
Keywords: anticancer drugs, cancer therapy, cell cycle, cell cycle arrest, cyclins, cyclin dependent kinase(cdk), cdk inhibitors
Abstract: The cell cycle is a highly conserved and ordered set of events, culminating in cell growth and division. It is tightly controlled by many regulatory mechanisms that either permit or restrain its progression. The main families of regulatory proteins that play key roles in controlling cell cycle progression are the cyclins, the cyclin dependent kinases (Cdks), their substrate proteins, the Cdk inhibitors (CKI) and the tumor suppressor gene products, p53 and pRb. Many cell cycle control genes, when deregulated, can cause cells that are not dividing to enter the cell cycle and begin to proliferate leading to cancer development. They do so by interfacing with the basic cell cycle-regulatory machinery to activate cell cycle entry. There is at present much optimism about the possibility of finding anticancer drug treatment strategies that modulate cell cycle regulatory molecules. Candidate targets for such strategies include crucial cell cycle molecules involved in G1 to S phase or G2 to M phase transition. This review will outline the basic regulatory machinery responsible for catalyzing cell cycle entry and describe the latest advances made in the field of cell cycle regulation. The basis of targeting the cell cycle particularly the Cdks as an approach to developing novel, specific and perhaps more effective anticancer treatments will be discussed. Examples of novel cell cycle-targeting agents that are in, or are close to being in clinical trials will be provided.
Export Options
About this article
Cite this article as:
Gali-Muhtasib Hala and Bakkar Nadine, Modulating Cell Cycle: Current Applications and Prospects for Future Drug Development, Current Cancer Drug Targets 2002; 2 (4) . https://dx.doi.org/10.2174/1568009023333809
DOI https://dx.doi.org/10.2174/1568009023333809 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Recent Patents on Biomarkers New Developments in Systemic Therapy for Hepatocellular Carcinoma
Current Cancer Therapy Reviews Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics Update on the Management of Spondyloarthritis in Asian Countries
Current Rheumatology Reviews Transition Metal Based Anticancer Drugs
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Metabolism in the Tumor Microenvironment: What is Known about Stromal and Immune Cells?
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Androgen Receptor: Past, Present and Future
Current Drug Targets Measles Virus as An Oncolytic Vector Platform
Current Gene Therapy HspB1 Dynamic Phospho-Oligomeric Structure Dependent Interactome as Cancer Therapeutic Target
Current Molecular Medicine Early Development of Cyclin Dependent Kinase Modulators
Current Pharmaceutical Design Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research Recent Progress in the Development of Natural ent-Kaurane Diterpenoids with Anti-tumor Activity
Mini-Reviews in Medicinal Chemistry Metabolic Features of Melanoma: A Gold Mine of New Therapeutic Targets?
Current Cancer Drug Targets Mechanisms for the Selective Actions of Vitamin D Analogues
Current Pharmaceutical Design Aging as an Epigenetic Phenomenon
Current Genomics Pharmacophore Development and SAR Studies of Imidazoline Receptor Ligands
Mini-Reviews in Medicinal Chemistry CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia
Cardiovascular & Hematological Disorders-Drug Targets Pharmacological Properties of Thalidomide and its Analogues
Recent Patents on Inflammation & Allergy Drug Discovery Using Naïve Bayes Algorithm to Estimate the Response to Drug in Lung Cancer Patients
Combinatorial Chemistry & High Throughput Screening